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Abstract
Background: Recent findings suggest a role of oxidative stress in the pathogenesis of Behcet’s disease (BD), but
the utility of oxidative stress-associated assays in offering diagnostic information or in the monitoring of disease
activity is largely unassessed.
Objective and methods: We aimed to measure oxidative and inflammatory markers, along with the markers of
reactive nitrogen species, S-nitrosothiols and 3-nitrotyrosine, in BD patients (n = 100) and healthy volunteers (n =
50). These markers were evaluated in regard to their role in the pathogenesis of BD as well as their relation to
clinical presentation, disease activity and duration.
Results: Median values for erythrocyte sedimentation rate (ESR), C-reactive protein, leukocyte count, and IL-18
levels, as well as myeloperoxidase (MPO) activity, were statistically higher in the patient group compared to
controls. Some inflammation markers (ESR, neutrophil and leukocyte counts) were statistically higher (p < 0.05) in
the active period. In contrast, oxidative stress-associated measures (erythrocyte lipid peroxidation, antioxidant
enzymes and measures of serum antioxidant capacity), revealed no statistically significant differences between the
median values in BD patients versus healthy control subjects (p > 0.05 in all statistical comparisons), nor was there
any difference in median levels of these oxidative stress markers in active disease versus disease remission. S-
nitrosothiols and 3-nitrotyrosine were undetectable in BD plasma.
Conclusions: The application of oxidative stress-associated measures to BD blood samples offered no
supplemental diagnostic or disease activity information to that provided by standard laboratory measures of
inflammation. S-nitrosothiols and 3-nitrotyrosine appeared not to be markers for active BD; thus the search for
biochemical markers that will indicate the active period should be continued with larger studies.
Keywords: Behçet’s disease, inflammation, cytokines, S-nitrosothiols, nitrotyrosine, electron paramagnetic resonance
spectrometry, nitric oxide, oxidative stress
Background
Behcet’s disease (BD) is a multisystem, chronic inflam-
matory, relapsing disorder that is characterized by oral
and genital ulcerations and ocular, arthritic, vascular
and neurological involvement. Its diagnosis is generally
clinical with a higher endemic rate in Turkey, Iraq, Iran,
Korea and Japan. There is no biochemical parameter
showing the active phase of the disease, other than non-
specific tests of CRP, erythrocyte sedimentation rate and
increased leukocyte count [1]. Although the etiology is
unclear, viruses, autoimmune mechanisms and toxic
agents have been suggested [1]. Recent findings indi-
cated that oxidative stress and an insufficient antioxi-
dant system might have roles in BD pathogenesis. It has
been suggested that increased phagocytic cell activity in
BD increases reactive oxygen and nitrogen species [2]
which lead to severe inflammatory and degenerative
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proteins, fatty acids and polysaccharides [3].
Vascular inflammation is one of the important fea-
tures of BD [1,4]. NO is an important mediator of
immunity and inflammation [2]. Thus NO is associated
with various inflammatory and autoimmune diseases
such as rheumatoid arthritis [5,6]. However, determina-
tion of the plasma levels of NO is difficult due to the
instability of the molecule and its conversion to reaction
products: nitrite (NO2
-), nitrate (NO3
-), S-nitrosothiols
(RSNOs) and 3-nitrotyrosine (3-NT). Recently increases
in nitrite and nitrate concentrations have been shown in
BD patients and were associated with disease activity
[7,8]. However, there is limited information on the
potential role of RSNO and 3-NT formation in BD.
In the present study we assessed, in BD patients, stan-
dard measures of inflammation (CRP, ESR, leukocyte
count), proinflammatory cytokine levels (TNF-a, IL-18),
Trolox equivalent antioxidant capacity (TEAC), ferric
reducing antioxidant power (FRAP), total antioxidant
enzyme activity (AOA), catalase (CAT), superoxide dis-
mutase (SOD) and myeloperoxidase (MPO) activities.
RSNO and 3-NT levels were also investigated. All these
markers were evaluated in regard to their relation to the
disease activity and clinical presentation in BD patients,
as well as their role in the pathogenesis of BD. It was
anticipated that the results could help to identify a para-
meter that can be helpful in clinical practice to deter-
mine disease activity.
Methods
Subjects
One hundred patients with BD (36 female, 64 male; age
mean ± S.D. 39.1 ± 9.7 years), and 50 sex-matched (20
female, 30 male) and age-matched (38.0 ± 6.6 years)
healthy volunteers as control subjects were included in
the study. All BD patients fulfilled the diagnostic criteria
of the International Study Group for BD [9]. This
means that every single patient had oral ulcers plus two
of the other four criteria. However, 13 patients fulfilled
these criteria only with mucocutaneous findings, i.e. oral
and genital ulcers plus relevant skin lesions. On the
other hand, 27 patients had uveitis as the dominant clin-
ical feature. Among the other clinical features not
included in the diagnostic criteria, vascular involvement
and articular involvement were additionally present in
21 and 18 BD patients, respectively. The remaining 18
patients had combinations of various involvements of
BD. Patients were also divided into 2 groups, as the
active and remission groups. At the time of the clinical
assessment, patients were included in the active group if
they had at least two of the following clinical findings:
mouth ulcers, genital ulceration, active uveitis, skin
findings, recent arthritis and vascular involvement.
Among the 100 patients, 74 were in the remission per-
iod, and the others (n = 26) were in an active period.
for BD [9]. The study was approved by the Ethics Com-
mittee of Ege University Medical School and informed
consent was obtained from all subjects.
Blood sample preparation
Blood samples were collected in heparin-containing
tubes, EDTA-containing tubes and anticoagulant-free
tubes after an overnight fast. Plasma and serum were
separated immediately. Erythrocyte lysates were pre-
pared [10] and polymorphonuclear (PMN) leukocytes
were isolated [11] from the heparin-containing tubes.
For S-nitrosothiol analysis, 0.7 mL plasma was added to
an aqueous solution of 250 μM N-ethylmaleimide
(NEM; 10 μL: Sigma-Aldrich, E1271-5 G) for 20 min
before the storage of the samples [5]. Samples were
stored at -80° until analysis.
Serum analyses
TNF-a and IL-18 levels were measured using enzyme-
linked immunosorbent assay (ELISA) kits (Biosource,
Cat. No.: KHC3011, USA, Biosource, Cat. No.:
KHC0181, USA) according to the manufacturers’
instructions. AOA (total antioxidant activity) was deter-
mined spectrophotometrically [12]. A solution of 0.1
mM 1,1-diphenyl-2-picrylhydrazil was rapidly mixed
w i t ht h es a m p l e( 1 / 1 0 ,v / v ) .T h ed e c l i n ei na b s o r b a n c e
was recorded at 550 nm against an ethanol blank over a
period of 15 min in a microplate reader (Thermo Lab-
systems, Multiskan EX instrument, which was also used
for all subsequent spectrophotometric assays). The
decrease in absorbance corresponding to 100% radical
scavenging was determined with a solution of pyrogallol
in dimethyl sulfoxide (ca. 0.5%), which caused complete
scavenging within seconds.
TEAC was determined spectrophotometrically [13].
ABTS 2,2’-azinobis3-ethylbenzthiazolinesulfonate; 7
mM) and potassium persulphate (4.95 mM) were mixed
(1/1 v/v) and stored at room temperature for 12 h
before use. This reactant was diluted with phosphate
buffer (1/25 v/v) until the absorbance value reached up
1.0-1.5. The working solution (975 μL) was mixed with
5-25 μL serum and absorbances were read at 734 nm
wavelength. Phosphate buffer and Trolox were used for
controls and standards, respectively.
FRAP was determined spectrophotometrically [14]. A
mixing solution (10:1:1, v/v/v) of acetate buffer (10 mM,
pH = 3,6), 2,4,6-tripyridyl-S-triazine (TPTZ; 10 mM)
and FeCl3 (20 mM) was added to the serum sample and
incubated at room temperature for 30 min. Readings
were done at 620 nm.
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RSNO concentrations were measured using a previously
described EPR spectrometry method [5] in 15 plasma
samples. In this technique the RSNOs were degraded at
an alkaline pH (pH 10,4), and the NO
￿ released was
measured in the presence of the spin trap complex
(MGD)2-F e
2+, in which MGD is N-methyl-D-glucamine
dithiocarbamate. In order to concentrate S-nitrosothiols
and further improve the detection limit for S-nitro-
sothiols, the EPR method was modified using different
techniques such as ultrafiltration (Whatman ultrafiltra-
tion devices), incubation of the samples at different tem-
peratures (room temperature, 50°C) and different time
intervals (1, 2, and 5 min) and enzymatic proteolysis
was carried out using proteinase K and pronase. Each
procedure was performed several times.
Nitrotyrosine (3-NT) concentrations were investigated
with an enzyme-linked immunosorbent assay using a
commercial kit (Hycult Biotechnology, The Netherlands;
Cat. No.: HK501). This 3-NT ELISA test kit is based on
the sandwich method. All samples were diluted 1:20
prior to conducting the assay.
Blood cell-based assays
Isolation of polymorphonuclear (PMN) leukocytes and MPO
assay
Heparinized blood samples were diluted with an equal
volume of phosphate buffered saline (PBS) and then 4
mL of Ficoll Hypaque (Sigma-Aldrich-1077) was added
to each sample and centrifuged for 20 min at 1200 g.
After centrifugation, the leukocyte pellet was taken and
mixed with 0.9% NaCl. This mixture was centrifuged for
5 min at 1500 g. The cell pellet that contained the PMN
was then resuspended in phosphate buffer and stored at
-80°C until analysis. Leukocyte MPO activities were
measured according to the modified method of Grisham
et al. [15]. Briefly, following homogenization, leukocyte
pellets were rehomogenized in 0.5% HETAB (hexadecyl-
trimethyl ammonium bromide) in phosphate buffer (50
mM, pH = 6.0). Following three freeze-thaw cycles, sam-
ples were centrifuged at 10,000 rpm for 10 min. Super-
natants were added to a reaction solution containing 0.5
M o-dianisidine (in phosphate buffer). After addition of
hydrogen peroxide solution (20 mM), absorbances of
samples were recorded at 492 nm with a microplate
reader during 3 minutes with 15 s intervals. Protein
concentration was measured according to Lowry’s
method [16].
Preparation of erythrocyte haemolysates, followed by eSOD,
eCAT and eTBARS assays
After separation of plasma, the packed erythrocytes were
washed twice with 9 g⁄L NaCl and haemolysed with ice-
cold water (1/5, v/v) Erythrocyte SOD (eSOD), eythro-
cyte catalase (eCAT) and erythrocyte TBARS (e-TBARS)
activities were determined immediately in haemolysates.
The haemoglobin values were measured by Drabkin’s
method [17].
Erythrocyte SOD (eSOD) activity was measured spec-
trophotometrically using a commercial kit (RANDOX,
UK, cat no. SD 125). This method is based on the use
of xanthine and xanthine oxidase (XOD) to generate
superoxide radicals which react with a chromogen solu-
tion to form a red formazan dye. SOD activity is then
measured by the degree of inhibition of this reaction by
means of the decrease in absorbance at 490 nm. This
result was normalised to the Hb concentration, and
SOD activity was expressed as units/g Hb.
Erythrocyte CAT (eCAT) activities were determined as
described by Sozmen et al. [7], in which the degradation
of H2O2 was recorded spectrophotometrically at 240
nm. One unit of CAT was defined as the amount of
enzyme that decomposes 1 μm0l H2O2 /min.
Polyunsaturated fatty acids are oxidized due to
increased oxidant stress resulting in high plasma TBARS
levels. Erythrocyte TBARS (eTBARS) levels were deter-
mined according to the method previously reported
[18]. After dilution of hemolysates with physiologic sal-
ine, they were incubated with TBA-working solution
(0.12 M TBA in 15% TCA and 1% HCl) for 30 min at
95°C. eTBARS concentrations were calculated using a
calibration curve constructed from 1,1,3,3-
tetraethoxypropane.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism v5.04. Data were not normally distributed, and were
expressed as median values with interquartile ranges. Data
were analyzed by the Kruskal-Wallis test, and Mann-
Whitney U test to compare the median values of two
groups. Correlations between variables were tested using
Spearman’s rank correlation. P values less than or equal to
0.05 were evaluated as statistically significant.
Results
The results of all parameters, when comparing the
group of healthy subjects (n = 50) with all BD patients
analysed (n = 100) are given in Table 1 except the
plasma RSNO (n = 15) and 3-NT (n = 53) concentra-
tions which were below the detection range in both
patient and healthy control groups. As expected, mea-
s u r e so fi n f l a m m a t o r yr e s p o n s e ,i . e .E S R ,C R P ,l e u k o -
cytes, IL-18 and MPO activity, were statistically higher
in the patient group compared with control group (all p
< 0.0001). In contrast, oxidative stress-associated mea-
sures, i.e. e-TBARS, e-SOD, e-CAT, AOA, FRAP and
T E A C ,r e v e a l e dn os t a t i s t i c a lly significant differences
between the median values in patients versus healthy
control subjects (p > 0.05 in all statistical comparisons).
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(n = 26) and remission (n = 74) phases of the disease
are given in Table 2. The median values for ESR, CRP
and leukocyte count were statistically higher in active
disease patients, compared with patients in remission (p
< 0.0001, p < 0.0001 and p = 0.004, respectively), while
none of the other parameters showed statistically signifi-
cant increases in the active disease group compared
with the patients in remission (p > 0.05). Indeed, the
median serum TNF-a concentration showed a trend (p
= 0.06) towards being lower in patients with active dis-
ease than those in remission.
Positive correlations were found between the concen-
trations of established markers of inflammation (ESR,
CRP and leukocyte count) in patients with BD. R values
for the correlations of all markers are given in Figure 1.
Although other statistically significant correlations were
observed between various parameters measured in this
study, none of the correlations were as strong as those
observed when correlating one inflammatory marker
with another inflammatory marker, and none of the oxi-
dative stress-associated markers were found to correlate
strongly with ESR, CRP or leukocyte count. The stron-
gest positive correlation was found between eTBARS
Table 1 Standard laboratory indices and oxidative stress-associated measures in BD patient and healthy control
groups.
Control Subjects BD Patients P value
ESR (1 h) 7.0 (5.0-10.0) n = 50 11.5 (7.0-21.3) n = 100 < 0.0001
CRP (mg/L) 0.09 (0.05-0.11) n = 50 0.36 (0.10-2.20) n = 98 < 0.0001
Leukocytes(10
3/mm
3) 5300 (4800-6200) n = 43 7250 (6100-9300) n = 98 < 0.0001
TNF-a (pg/mL) 2.74 (1.26-3.70) n = 33 3.43 (1.76-4.70) n = 82 0.093
IL-18 (pg/mL) 181.4 (117.2-245.6) n = 37 263.4 (193.9-375.3) n = 100 < 0.0001
MPO (U/mg protein) 1.19 (0.45-2.99) n = 37 3.86 (1.70-5.86) n = 93 < 0.0001
e-TBARS (nmol/gHb) 27.1 (23.7-29.6) n = 38 28.4 (25.0-32.9) n = 100 0.175
e-SOD (U/gHb) 674.4 (417.4-913.4) n = 38 621.4 (427.5-1026.0) n = 99 0.838
e-CAT (U/gHb) 4711 (3968-5373) n = 38 5105 (4419-5914) n = 100 0.110
AOA (%) 34.9 (27.3-49.5) n = 40 42.1 (31.8-51.3) n = 89 0.304
FRAP (μmol/L) 864.9 (728.5-1050.0) n = 33 773.0 (675.3-896.6) n = 99 0.056
TEAC (trolox equivalent) 4.69 (4.01-4.98) n = 33 4.68 (4.20-5.18) n = 100 0.560
Data are expressed as median (interquartile range) values
ESR = Erythrocyte sedimentation rate, CRP = C-reactive protein, TNF-a = tumor necrosis factor-a, IL = interleukin, MPO = myeloperoxidase, e-TBARS = erythrocyte
thiobarbituric acid reactive substances, e-SOD = erythrocyte superoxide dismutase, e-CAT = erythrocyte catalase, AOA = antioxidant activity, FRAP = ferric
reducing antioxidant power, TEAC = Trolox equivalent antioxidant capacity
Table 2 Results in regard to active and remission phases of the disease.
Remission Active P value
Age 41.22 ± 9.50 n = 74 32.96 ± 7.80 n = 26 0.0001
Disease duration (years) 9.5 (5.0-15.0) n = 74 6.5 (4.0-12.0) n = 26 0.046
ESR (1 h) 9.0 (6.0-17.0) n = 73 27.0 (11.5-49.5) n = 25 < 0.0001
CRP (mg/L) 0.22 (0.10-0.80) n = 73 2.70 (1.02-6.20) n = 25 < 0.0001
Leukocyte (10
3/mm
3) 7100 (5850-8450) n = 73 9000 (7200-11800) n = 25 0.004
TNF-a (pg/mL) 3.63 (1.99-5.26) n = 66 1.99 (1.34-3.90) n = 16 0.060
IL-18 (pg/mL) 280.0 (202.0-379.0) n = 74 213.4 (171.5-306.7) n = 26 0.040
MPO (U/mg protein) 3.67 (1.61-5.76) n = 73 4.81 (2.08-7.21) n = 20 0.339
e-TBARS (nmol/g Hb) 29.2 (26.0-33.9) n = 74 26.6 (22.4-29.9) n = 26 0.042
e-SOD (U/gHb) 646.1 (406.9-1069) n = 74 532.3 (437.9-970.0) n = 25 0.429
e-CAT (U/gHb) 5122 (4510-5952) n = 75 4749 (4235-5705) n = 26 0.432
AOA (%) 40.6 (30.2-50.3) n = 66 44.6 (37.4-52.3) n = 23 0.267
FRAP (μmol/L) 775.9 (692.5-951.2) n = 73 737.1 (625.0-839.8) n = 26 0.112
TEAC (Trolox equivalents) 4.68 (4.20-5.10) n = 74 4.70 (4.11-5.26) n = 26 0.867
Data are expressed as median (interquartile range) values, and were analysed using the Mann- Whitney U test, with the exception of age which is expressed as
mean ± SD and was analysed by unpaired Student’s t-test
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Page 4 of 8and TNF-a (r = 0.289, p = 0.008), whilst the strongest
negative correlation was observed between MPO and
FRAP (r = -0.343, p = 0.001). These may indicate the
close relation between oxidative stress and inflammatory
processes in BD pathophysiology.
Neither inflammatory parameters nor oxidative stress-
associated parameters showed any statistically significant
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MPO   0.185 0.036 0.039 0.232*  0.048 
e-
TBARS  
0.041  -0.202*  0.009 0.289* 0.238* 0.254*     
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Figure 1 Spearman’s rank correlation coefficients (r values) for standard laboratory indices and oxidative stress-associated measures
in Behcet’s disease patients.
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ocular, vascular, articular or mucocutaneous involve-
ment (data not shown). There were also no significant
correlations between any of the measured parameters
and disease duration.
Discussion
In the present study, we explored the potential utility of
measures of oxidative stress in monitoring disease activ-
ity, and in the diagnosis of complications, in BD
patients. We applied a broad panel of widely adopted
oxidative stress-associated measures to plasma, serum
and erythrocyte samples. These measures were carried
out in conjunction with both standard laboratory assays
of the inflammatory response, such as CRP and ESR,
and clinical assessments. We aimed to assess the addi-
tional clinical information that measures of oxidative
stress might provide in terms of disease activity or the
diagnosis of complications.
As expected, the group of BD patients showed evi-
dence of a substantial inflammatory response, as indi-
cated by high median levels of CRP, ESR, blood
leukocyte count, MPO and IL-18, compared with
healthy, age- and sex-matched control individuals.
Moreover, when the BD group was subdivided into
active disease and remission subgroups, some of these
inflammatory measures were clearly elevated in the
active disease subgroup compared with the remission
subgroup. In contrast - and as expected - measures of
inflammation provided no obvious indication of clinical
complications or disease duration. Thus, our findings
with standard inflammatory measures are consistent
with their known nonspecific increase in BD. None of
these markers can be defined to be a specific measure
for disease activity or an indicator of any complication.
[19]
TNF-a is an important proinflammatory cytokine and
it has been implicated in the pathogenesis of many
inflammatory and autoimmune diseases such as sepsis,
inflammatory intestinal disease [20] and RA [21]. Similar
to these studies, Oztas et al [22] have shown the role of
this cytokine in BD patients. Our study found no statis-
tically significant evidence of elevated TNF-a concentra-
tions in serum samples from patients versus healthy
subjects, nor in BD patients with active disease versus
patients in remission. This might be due to the presence
of other proteins released in the active period which
interfere with the TNF-a measures or lack of ability of
the current assay to detect TNF-a that had been com-
plexed by the soluble TNF receptor. Our results demon-
strate that serum TNF-a is not a reliable biomarker of
either the presence of BD or of disease activity.
Recently, Musabak and colleagues [23] and Lee and
colleagues [24] independently showed the role of
another proinflammatory cytokine, IL-18, in the patho-
genesis of BD. It was proposed that IL-18 probably
directs the immune response in BD toward the T helper
1 type pathway. This hypothesis was supported by high
serum levels of IL-18 in inactive patients, indicating an
ongoing T helper polarization and subclinical inflamma-
tion during the inactive period. Interestingly, we also
observed higher IL-18 levels in the BD patient group
when compared with controls. In regard to IL-18 con-
centrations in active and remission periods, the differ-
ence between the median values in the two groups was
less marked, although still statistically significant. This
may be due to the subclinical inflammation during the
inactive period, as proposed previously [23].
Increased neutrophil activation is observed in BD
patients and this can directly be determined with MPO
activities. In accordance with previous studies [25,26],
leukocyte MPO activity was higher in the BD patient
group than the control group in our study. In addition,
the weak positive correlation found between leukocyte
MPO activity and serum TNF-a in BD patients (r =
0.232, p = 0.041) demonstrates the concomitant increase
in neutrophil activation and inflammation markers in
BD.
The strong negative correlation between leukocyte
MPO activity and FRAP (r = -0.343, p = 0.001) in this
study shows the importance of the oxidant/antioxidant
balance in BD patients. In inflammatory diseases such as
BD, MPO production from activated neutrophils is
increased, which could be consistent with oxidative
stress. Also consistent with oxidative stress, plasma anti-
oxidant activity in BD is reportedly decreased [27].
Although increased oxidative stress has been sug-
gested to be another hallmark of BD [2,28,29], the pre-
sent study provides little evidence to support this idea,
despite the clearly inflamed status of the BD group. Pre-
viously, a number of studies have shown an increase in
serum TBARS and eTBARS concentrations in BD
patients [27,30,31]. In contrast, our study showed no
evidence that eTBARS levels were higher in patients
than controls.
In the present study, when patients were grouped for
ocular, vascular, articular and mucocutaneous involve-
ments, the measured parameters did not show statisti-
cally significant differences between groups. In contrast,
Taysi et al. [32] have shown a high serum MDA level
and SOD activity in patients with ocular involvement.
We also found no correlations between measures of oxi-
dative stress and disease duration. In this respect, our
results are in concordance with other related literature
[33].
It has been proposed that NO plays a role in the
pathogenesis of BD. Laroux et al. [34] showed that NO
modulates the adhesion molecules induced by cytokines
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suggested that increased NO release from the endothe-
lium is expected in BD patients due to enhanced leuko-
cyte-endothelium interactions. Previously increases in
NO production due to various forms of the tissue injury
in inflammation have been shown [36]. In recent years
studies showed that S-nitrosothiols, formed by the reac-
tion of reactive nitrogen species (derived from NO) with
free thiols, are increased in biologic systems as a
response to inflammatory reactions [5,37]. In the current
study RSNOs in the plasma of BD and control subjects
were not within the detection limit of the analytical
technique (EPR spectrometry with spin trapping). The
technique was further applied with various preanalytical
and analytical modifications such as ultrafiltration, incu-
bating at alternative temperatures and time, and enzy-
matic proteolysis. Despite all these modifications,
RSNOs could not be detected and this is attributed to
their very low levels in BD plasma. Previously, RSNOs
were detected in plasma and synovial fluid from rheu-
matoid arthritis patients, but seldom in healthy control
subjects [5].
Recently 3-NT, which is produced by nitration of
tyrosine by reactive nitrogen species has been sug-
gested to be a useful marker for inflammation and
N O - m e d i a t e dt i s s u ei n j u r y[ 3 8 , 3 9 ] .B o t ht h ef r e ea n d
protein-bound nitrotyrosine forms are increased in var-
ious tissues in inflammatory disorders such as athero-
sclerotic plaques, intestinal tissue of inflammatory
bowel disease patients, and lung tissue of adults with
respiratory distress syndrome [40-42]. In our study, we
aimed to determine whether the local formation of 3-
NT in the inflammatory processes in BD is also sys-
temically detectable. In our previous work investigating
the 3-NT levels in RA patients [43], a proportion of
both plasma and SF samples from RA patients had
detectable 3-NT levels with the ELISA sandwich
method used. However, in the current study no detect-
able 3-NT was observed in BD patients or controls
with the same method. This was also in contrast to the
findings of epnr et al [30].
In conclusion, in agreement with previous studies
[22,23,25,27], significant increases in BD patients com-
pared with healthy control subjects, were observed in
ESR, CRP, leukocyte count, IL-18, and MPO enzyme
activity, indicating the activation of leukocytes and
macrophages in the inflammatory process. However, in
contrast to previous studies, we found that the assays
used appeared to offer no potential for providing addi-
tional insight into disease activity or the diagnosis of
disease complications. RSNOs and 3-NT, which are
linked to NO metabolism and are proposed to play a
role in the pathogenesis of BD, were not proved to be
markers for the active period of BD. We propose that
the search for a biochemical marker that will indicate
the active period in BD should be continued with new
(more specific and sensitive) measures of oxidative
stress, and in larger studies.
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